Welcome to our dedicated page for Evolent Health news (Ticker: EVH), a resource for investors and traders seeking the latest updates and insights on Evolent Health stock.
Evolent Health, Inc. (NYSE: EVH) regularly issues news and updates that reflect its focus on better health outcomes for people with complex conditions and on specialty care solutions for payers and providers. Company news often highlights developments in oncology and other complex specialties, financial performance, strategic transactions and leadership changes.
Investors and industry observers following EVH news can expect recurring coverage of quarterly and annual financial results, including revenue and adjusted EBITDA metrics and management commentary on demand for complex specialty care solutions. Evolent frequently reaffirms or updates its financial guidance through press releases and related 8-K filings, and schedules conference calls and webcasts to discuss these results.
Evolent’s news flow also features clinical and partnership initiatives. For example, the company has announced a national partnership with American Oncology Network to introduce a model for cancer care that seeks to improve quality and affordability while reducing reliance on prior authorization. This model incorporates quality initiatives, AI-driven clinical insights through the MiBA analytics platform, payment innovation, and care navigation programs that use a cancer care management platform to support patients.
Corporate and capital markets announcements form another key part of EVH news. Recent items include the pricing and issuance of 4.50% convertible senior notes due 2031, repurchases of existing convertible notes and Class A common stock, and amendments to credit agreements and commitment letters for incremental financing facilities. Evolent also publishes updates on strategic portfolio actions, such as the divestiture of its value-based primary care business, Evolent Care Partners, to Privia Health Group, Inc.
Governance and leadership updates appear in the news as well, including appointments to executive roles, changes in the Chief Financial Officer position, and board retirements and appointments. For readers tracking EVH, this news page offers an ongoing view into how the company communicates its financial performance, specialty care initiatives, capital structure decisions and organizational evolution.
Evolent Health (NYSE: EVH) announced a Cooperation Agreement with Engaged Capital, appointing Craig Barbarosh to its Board of Directors as a Class III director. A Strategy Committee will be created to enhance operational efficiency and financial performance. Evolent also plans to amend its Charter to declassify the Board, allowing directors to stand for one-year terms post-2021 Annual Meeting. Engaged Capital emphasizes its commitment to maximizing shareholder value. This move aims to strengthen governance and strategic direction for Evolent's future.
Evolent Health (NYSE: EVH) announced participation in the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021. CEO Seth Blackley and CFO John Johnson will present virtually at 9:10 a.m. ET. A live audio-only webcast will be accessible via Evolent's investor relations page.
Evolent Health provides clinical and administrative solutions that enhance health care efficiency and affordability, serving leading payers and providers nationwide. The company has received national recognition for its population health programs and work environment.
Evolent Health, a leading health care solutions provider, announced that CEO Seth Blackley and CFO John Johnson will participate in 1x1 meetings at the 32nd Annual Piper Sandler Healthcare Conference on December 2, 2020. Meetings can be arranged through Piper Sandler. Evolent focuses on improving health care affordability and delivery with a range of services, including total cost of care management. The company has received national recognition for its innovative approach and workplace environment.
Summary not available.
Evolent Health (NYSE: EVH) has partnered with Florida Blue Medicare to provide comprehensive oncology specialty management services through its subsidiary, New Century Health. This collaboration aims to manage the cost and quality of oncology care for 125,000 Medicare Advantage members across Florida's network of 1,000 physicians in 67 counties. The initiative focuses on evidence-based clinical pathways and aligned payment models to enhance patient outcomes and reduce costs. Full health plan operations are set to begin on January 1, 2021.
Evolent Health (NYSE: EVH) reported its Q3 2020 results with a revenue of $264.6 million, marking a 20.2% year-over-year increase. Despite the revenue growth, the company faced a net loss of $(37.3) million. Adjusted EBITDA improved to $12.7 million from $3.3 million in Q3 2019. The company announced new partnerships and completed the Passport Health Plan asset sale, enhancing operational efficiencies. Evolent has a cash position of $387 million as of September 30, 2020, and aims to optimize capital allocation for long-term shareholder value.
Evolent Health (NYSE: EVH) will release its third quarter 2020 operating results on November 5, 2020, after market close. Following the release, a conference call will be held at 5:00 p.m. Eastern Time. Investors can join the call by dialing 855.940.9467 or 412.317.6034 for international participants. The call will include details about Evolent's clinical and administrative solutions aimed at enhancing health care affordability and quality. An audio replay will be available on Evolent's investor relations website for one week post-call.
Evolent Health (NYSE: EVH) hosted a virtual Investor and Analyst Day on September 29, 2020, presenting its strategy to enhance shareholder value and operational updates. The Company targets approximately 30% year-over-year adjusted services revenue growth for 2020 and aims for mid-teens annual growth in the medium term. Key announcements include partnerships with Physicians Accountable Care of Utah and Tar River Health Alliance, cost-cutting measures targeting $20-25M in SG&A expenses for 2021, and a focus on achieving a mid-teens Adjusted EBITDA margin. Adjusted Revenue guidance for Q3 2020 is set between $258M-272M.
Evolent Health (NYSE: EVH) will hold its annual Investor and Analyst Day on September 29, 2020, from 10:00 a.m. ET to 12:30 p.m. ET virtually. Interested participants can register and find the live webcast on the company's investor relations website. A replay will also be available post-event. Evolent Health specializes in clinical and administrative solutions to enhance health care affordability and simplicity, serving a diverse range of payers and providers nationwide. The company is recognized for its innovative approaches and quality health solutions.
Evolent Health (NYSE: EVH) will have its CEO Frank Williams, President Seth Blackley, and CFO John Johnson participate in the Baird 2020 Global Healthcare Conference on September 10, 2020, at 9:05 a.m. ET. A live webcast can be accessed through the investor relations section of Evolent's website. Evolent Health specializes in clinical and administrative solutions aimed at improving healthcare quality and affordability, serving a broad base of payers and providers. The company is recognized for its population health program accreditation.